BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
OncoC4 creates a bispecific buzz
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
ESMO 2024 – Torl challenges BioNTech in Claudin6
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
ESMO 2024 – a role for immunotherapy in ovarian cancer
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
ESMO 2024 preview – Summit could take on Merck in breast cancer
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
